✉  info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Peripheral Neuropathy Market Research Report Information by Type (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy), by Treatment (Pharmacological Therapies {Pain Relievers, Anti-seizure Medications, Antidepressants}, Non-Pharmacological Therapies {Transcutaneous Electrical Nerve Stimulation, Plasma Exchange and Intravenous Immune Globulin}, Others), by End User (Hospitals and Clinics, Ambulatory Centers, Others), and By Region (North Amer


ID: MRFR/HC/7013-HCR | 111 Pages | Author: Kinjoll Dey| November 2024

Peripheral Neuropathy Market Segmentation


Peripheral Neuropathy Market Type Outlook (USD Billion, 2019-2030)




  • Diabetic Peripheral Neuropathy




  • Chemotherapy-induced Peripheral Neuropathy




  • Idiopathic Peripheral Neuropathy




  • HIV/AIDS Associated Peripheral Neuropathy




Peripheral Neuropathy Market Treatment Outlook (USD Billion, 2019-2030)




  • Pharmacological Therapies




    • Pain Relievers




    • Anti-seizure Medications




    • Antidepressants






  • Non-Pharmacological Therapies




    • Transcutaneous Electrical Nerve Stimulation




    • Plasma Exchange




    • Intravenous Immune Globulin






  • Others




Peripheral Neuropathy Market End User Outlook (USD Billion, 2019-2030)




  • Hospitals and Clinics




  • Ambulatory Centers




  • Others




Peripheral Neuropathy Market Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




    • North America Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • North America Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • North America Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • US Outlook (USD Billion, 2019-2030)




    • US Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • US Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • US Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Canada Outlook (USD Billion, 2019-2030)




    • Canada Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Canada Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Canada Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others








  • Europe Outlook (USD Billion, 2019-2030)




    • Europe Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Europe Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Europe Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Germany Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Germany Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • France Outlook (USD Billion, 2019-2030)




    • France Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • France Peripheral Neuropathy Market Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • France Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • UK Outlook (USD Billion, 2019-2030)




    • UK Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • UK Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • UK Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Italy Outlook (USD Billion, 2019-2030)




    • Italy Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Italy Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Italy Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Spain Outlook (USD Billion, 2019-2030)




    • Spain Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Spain Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Spain Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Rest Of Europe Outlook (USD Billion, 2019-2030)




    • Rest Of Europe Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Rest of Europe Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Rest of Europe Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others








  • Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Asia-Pacific Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Asia-Pacific Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Asia-Pacific Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • China Outlook (USD Billion, 2019-2030)




    • China Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • China Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • China Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Japan Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Japan Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • India Outlook (USD Billion, 2019-2030)




    • India Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • India Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • India Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Australia Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Australia Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • South Korea Outlook (USD Billion, 2019-2030)




    • South Korea Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • South Korea Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • South Korea Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Rest of Asia-Pacific Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Rest of Asia-Pacific Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others








  • Rest of the World Outlook (USD Billion, 2019-2030)




    • Rest of the World Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Rest of the World Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Rest of the World Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Middle East Outlook (USD Billion, 2019-2030)




    • Middle East Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Middle East Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Middle East Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Africa Outlook (USD Billion, 2019-2030)




    • Africa Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Africa Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Africa Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Peripheral Neuropathy Market by Type




      • Diabetic Peripheral Neuropathy




      • Chemotherapy-induced Peripheral Neuropathy




      • Idiopathic Peripheral Neuropathy




      • HIV/AIDS Associated Peripheral Neuropathy






    • Latin America Peripheral Neuropathy Market by Treatment




      • Pharmacological Therapies




        • Pain Relievers




        • Anti-seizure Medications




        • Antidepressants






      • Non-Pharmacological Therapies




        • Transcutaneous Electrical Nerve Stimulation




        • Plasma Exchange




        • Intravenous Immune Globulin






      • Others






    • Latin America Peripheral Neuropathy Market by End User




      • Hospitals and Clinics




      • Ambulatory Centers




      • Others







Research Methodology on Peripheral Neuropathy Market


Abstract


This report presents a comprehensive research methodology for the Market Research Future (MRFR) report on Peripheral Neuropathy. It discusses the research objectives and approaches, data collection methods and selection criteria for data sources, and analytical methods used in the research. It also outlines the key assumptions and limitations that informed the research. The methodology enables MRFR to undertake analytical investigations into the causes and impacts of Peripheral Neuropathy on the market and patients. It further helps MRFR to produce high-quality, accurate reports that meet the needs of its customers and support informed decision-making.


Introduction


Peripheral Neuropathy (PN) is a medical condition resulting in damage to the peripheral nerves. It can cause a range of symptoms including numbness, tingling, burning, or painful sensations in the hands and feet, muscle weakness, muscle cramps and fatigue, loss of reflexes, and even cognitive impairment. It is typically caused by certain underlying conditions or diseases, like diabetes, traumatic injuries, exposure to certain drugs and toxins, and even genetic causes. PN affects over 20 million people in the US alone, and its incidence is projected to rise over the coming years as the population ages and diabetes prevalence increases. Treatment options for PN include medications, physical therapy, dietary changes and lifestyle modifications, and alternative and complementary therapies.


For this report, MRF examined the global peripheral neuropathy market and its drivers, restraints, and opportunities. It also explored existing and potential treatments, developments in diagnostics and therapeutics, current and emerging clinical trials, and top companies operating in the market. To support its analysis, MRFR used various primary and secondary resources, such as expert interviews, industry surveys, and public data sources.


Research Objectives


The objective of this study is to produce an exhaustive report on the global peripheral neuropathy market, including its drivers, restraints, and opportunities. The objectives of the study were the following:



  • To identify, analyze, and forecast the global peripheral neuropathy market.

  • To identify the key drivers and restraints influencing the growth of the market

  • To analyze emerging trends, competitive strategies, and new product launches in the global peripheral neuropathy market

  • To profile the key companies operating in the global peripheral neuropathy market


Research Approaches Used


In this report, MRFR used a concurrent mixed methods design, which involved a combination of qualitative and quantitative research methods. This was employed to generate an accurate, comprehensive report on the global peripheral neuropathy market. MRFR used a range of primary and secondary sources to inform its analysis. This involved interviews with health professionals and experts in the field, industry surveys, and public data sources.


Data Collection Methods


MRFR employed a variety of data collection methods to obtain the necessary data for the report. These included expert interviews, industry surveys, and public data sources. MRF used a structured questionnaire to conduct the interviews, which included open-ended questions about the participants’ knowledge pertaining to the peripheral neuropathy market. Questions focused on various topics, such as their perceptions of the current market and their views on its potential future. Interviews were partially transcribed and then analyzed to look for common themes, which informed MRFR's analysis of the peripheral neuropathy market.


Secondly, MRFR undertook an industry survey to gain an understanding of the current industry landscape and available treatments for peripheral neuropathy. This survey is conducted online and respondents were asked about their experience with peripheral neuropathy, treatment preferences, and areas of unmet need.


Finally, MRFR accessed a range of public sources of data, such as studies, medical journals, patent documents, and clinical trials, to obtain the necessary information to inform the report.


Data Source Selection Criteria


In order to ensure that the data source for the report was of high quality, MRFR employed the following data source selection criteria. Sources of data were categorically assessed to ensure their relevance and accuracy. Sources were chosen based on the following criteria:



  • Relevance: The sources must be highly relevant to the research objectives, providing relevant and timely information on the peripheral neuropathy market.

  • Accuracy: Sources must present source able and verifiable data, as well as verified research results and conclusions.

  • Timeliness: Sources must be up to date, providing the latest information on the peripheral neuropathy market.

  • Unbiased and objective: Sources must be unbiased and objective, providing independent and authoritative data.


Analytical Methods Used


MRFR employed a range of analytical methods for the report, including qualitative data analysis, quantitative data analysis, and market modelling. For qualitative analysis, MRFR used content analysis to examine the expert interviews and industry survey responses to identify common themes and patterns. This enabled MRFR to develop meaningful insights into the views of experts and other market participants regarding the peripheral neuropathy market.


MRFR also employed quantitative analysis, based on the large amount of numerical data sourced. This involves descriptive statistics and data manipulation to look for trends and patterns in the data. Finally, MRFR used market modelling to develop a comprehensive view of the peripheral neuropathy market. This enabled MRFR to create forecasts and long-term projections for the market and its segments.


Conclusions


This report presents a comprehensive research methodology for the Market Research Future (MRF) report on Peripheral Neuropathy. It outlines the research objectives and approaches, data collection methods and selection criteria for data sources, and analytical methods used in the research. It also outlines the key assumptions and limitations that informed the research. The methodology enables MRFR to undertake analytical investigations into the causes and impacts of Peripheral Neuropathy on the market and patients. It further helps MRFR to produce high-quality, accurate reports that meet the needs of its customers and support informed decision-making along with the forecast from 2023 to 2030.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE

6.1. Overview

6.2. Diabetic Peripheral Neuropathy (DPN)

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.3. Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.4. Idiopathic Peripheral Neuropathy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.5. HIV/AIDS Associated Peripheral Neuropathy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Pharmacological Therapies

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.2.1. Pain Relievers

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.2.2. Anti-seizure Medications

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.2.3. Antidepressants

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.3. Non-Pharmacological Therapies

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.3.1. Transcutaneous Electrical Nerve Stimulation

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.3.2. Plasma Exchange and Intravenous Immune Globulin

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.4. Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.3. Ambulatory Settings

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.4. Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

9. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

11. COMPANY PROFILES

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Product Type Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Bristol Myers Squibb

11.2.1. Company Overview

11.2.2. Product Type Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Novartis

11.3.1. Company Overview

11.3.2. Product Type Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Eli Lilly and Company

11.4.1. Company Overview

11.4.2. Product Type Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Pfizer Inc

11.5.1. Company Overview

11.5.2. Product Type Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. GlaxoSmithKline plc

11.6.1. Company Overview

11.6.2. Product Type Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Merck and Co. Inc.

11.7.1. Company Overview

11.7.2. Product Type Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Cipla Limited

11.8.1. Company Overview

11.8.2. Product Type Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Lupin Limited

11.9.1. Company Overview

11.9.2. Product Type Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Dr. Reddy's Laboratories

11.10.1. Company Overview

11.10.2. Product Type Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. F. Hoffmann-La Roche Ltd.

11.11.1. Company Overview

11.11.2. Product Type Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. RxFunction, Inc.

11.12.1. Company Overview

11.12.2. Product Type Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SYNOPSIS, 2023-2030

TABLE 2 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET ESTIMATES & FORECAST, 2023-2030 (USD MILLION)

TABLE 3 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 4 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 5 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 6 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY REGION, 2023-2030 (USD MILLION)

TABLE 7 NORTH AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 8 NORTH AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 9 NORTH AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 10 US: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 11 US: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 12 US: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 13 CANADA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 14 CANADA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 15 CANADA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 16 LATIN AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 17 LATIN AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, TREATMENT, 2023-2030 (USD MILLION)

TABLE 18 LATIN AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 19 EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 20 EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 21 EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 22 WESTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 23 WESTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 24 WESTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 25 EASTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 26 EASTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 27 EASTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 28 ASIA-PACIFIC: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 29 ASIA-PACIFIC: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 30 ASIA-PACIFIC: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET

FIGURE 4 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 5 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 6 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 ABBOTT LABORATORIES: KEY FINANCIALS

FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE

FIGURE 17 BRISTOL MYERS SQUIBB: KEY FINANCIALS

FIGURE 18 BRISTOL MYERS SQUIBB: SEGMENTAL REVENUE

FIGURE 19 BRISTOL MYERS SQUIBB: REGIONAL REVENUE

FIGURE 20 NOVARTIS AG: KEY FINANCIALS

FIGURE 21 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 22 NOVARTIS AG: REGIONAL REVENUE

FIGURE 23 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 24 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 25 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 26 PFIZER INC: KEY FINANCIALS

FIGURE 27 PFIZER INC: SEGMENTAL REVENUE

FIGURE 28 PFIZER INC: REGIONAL REVENUE

FIGURE 29 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 30 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 31 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 32 MERCK AND CO. INC.: KEY FINANCIALS

FIGURE 33 MERCK AND CO. INC.: SEGMENTAL REVENUE

FIGURE 34 MERCK AND CO. INC.: REGIONAL REVENUE

FIGURE 35 CIPLA LIMITED: KEY FINANCIALS

FIGURE 36 CIPLA LIMITED: SEGMENTAL REVENUE

FIGURE 37 CIPLA LIMITED: REGIONAL REVENUE

FIGURE 38 LUPIN LIMITED: KEY FINANCIALS

FIGURE 39 LUPIN LIMITED: SEGMENTAL REVENUE

FIGURE 40 LUPIN LIMITED: REGIONAL REVENUE

FIGURE 41 DR. REDDY'S LABORATORIES: KEY FINANCIALS

FIGURE 42 DR. REDDY'S LABORATORIES: SEGMENTAL REVENUE

FIGURE 43 DR. REDDY'S LABORATORIES: REGIONAL REVENUE

FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS

FIGURE 45 F. HOFFMANN-LA ROCHE LTD.: SEGMENTAL REVENUE

FIGURE 46 F. HOFFMANN-LA ROCHE LTD.: REGIONAL REVENUE

FIGURE 47 RXFUNCTION, INC.: KEY FINANCIALS

FIGURE 48 RXFUNCTION, INC.: SEGMENTAL REVENUE

FIGURE 49 RXFUNCTION, INC.: REGIONAL REVENUE

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Related Reports
report-img
Diabetic Neuropathy Treatment Market Research Report - Global Forecast till 2032
report-img
Neuropathic Pain Market Research Report - Global Forecast till 2032
report-img
Fluoroquinolone Toxicity Syndrome Market
Press Release
Category icon
Peripheral Neuropathy Market: Growing prevalence of Diabetes, coupled with the Rising Geriatric P...
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
📞  +1 (855) 661-4441(US)
📞  +44 1720 412 167(UK)

© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)